- Home
- ALLR
as 06-27-2025 2:30pm EST
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 13.3M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 464.0K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.47 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.61 - $7.45 | Next Earning Date: | 08-04-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Allarity Therapeutics Inc. News
ALLR Breaking Stock News: Dive into ALLR Ticker-Specific Updates for Smart Investing
GlobeNewswire
12 hours ago
Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer
GlobeNewswire
16 days ago
Allarity Therapeutics Announces Changes to Board of Directors
GlobeNewswire
24 days ago
Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Action
GlobeNewswire
a month ago
Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer
GlobeNewswire
2 months ago
Allarity Therapeutics Announces Participation in Pharma Partnering Summit US
GlobeNewswire
2 months ago
Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment
GlobeNewswire
2 months ago
Allarity Therapeutics Presents Novel Drug Response Predictor—DRP®—for Daratumumab in Multiple Myeloma at AACR 2025
GlobeNewswire
3 months ago
Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
Compare ALLR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALLR Allarity Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.